Top Markets
Coin of the day
RegeneRx Biopharmaceuticals, Inc. RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

RGRX
Rangering i aksjer #42502
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the... RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
Aksjekurs
$0.0007
Sist synkronisert: 2026-08-11
Markedsverdi
$1.05K
Endring (1 dag)
0.00%
Endring (1 år)
250.00%
Land
US
Handel RegeneRx Biopharmaceuticals, Inc. (RGRX)

Kategori

Inntekter for RegeneRx Biopharmaceuticals, Inc. (RGRX)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til RegeneRx Biopharmaceuticals, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for RegeneRx Biopharmaceuticals, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR